Skip to content
DataLookout
Menu

NCT05322850

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 23 versions: 21 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Sep 2026 to Sep 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 50 words
    • Study completion pushed from Sep 2027 to Sep 2028
    • Secondary endpoints: details revised at 4 of 10 entries
    • Site details revised at 3 of 4 sites
  2. Notable Recruitment resumed after suspension
    • Site details revised at 4 of 4 sites
    • Collaborators: 2 to 1
    v22
  3. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Seeking additional funding sources
    • Site details revised at 4 of 4 sites
    v21
  4. Minor Site contacts updated at 1 of 4 sitesv19
  5. Minor Site contacts updated at 1 of 4 sitesv17
Show 15 earlier versionsHide 15 earlier versions
  1. Minor Study sites revised (4)v16
  2. Minor Site details revised at 1 of 4 sitesv15
  3. Minor Site details revised at 1 of 4 sitesv14
  4. Notable Trial status: Suspended to Recruiting
    • Study sites revised (4)
    v13
  5. Minor Study sites: 3 to 4v12
  6. Stopped Trial status: Recruiting to Suspended Sponsor's reason: no manufacturing slots available from sponsor
    • Site details revised at 3 of 3 sites
    v11
  7. Minor Start date: Aug 8, 2022 to Aug 16, 2022v10
  8. Minor Study sites: 2 to 3v9
  9. Minor Site details revised at 1 of 2 sitesv8
  10. Notable Trial status: Suspended to Recruiting
    • Site details revised at 2 of 2 sites
    v7
  11. Stopped Trial status: Recruiting to Suspended Sponsor's reason: awaiting manufacturing slots from sponsor
    • Study sites: 1 to 2
    v6
  12. Minor Site contact updatedv5
  13. Minor Start date changed from estimate of Sep 2022 to Aug 8, 2022v4
  14. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Eligibility criteria expanded, about 150 words
    • Primary endpoints: 1 to 2
    • Secondary endpoints: 11 to 10
    • Site details revised
  15. Minor Site contact updatedv2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Primary graft failure
Timeframe: 28 days
Secondary graft failure
Timeframe: 100 days

Secondary (10)

Non-relapse mortality (12 months post-transplant)
Non-relapse mortality (24 months post-transplant)
Overall survival
Relapse rate (12 months post-transplant)
Relapse rate (24 months post-transplant)
Show 5 moreShow less
Rate of acute GVHD
Rate of chronic GVHD
Serious infection rate
Treatment-Emergent Adverse Events
Graft-versus-host disease (GVHD)-free, relapse-free survival

Arms and interventions

Orca-QExperimental

Biologicals: Orca-Q

Sites

4 sites in 1 country